| UPDATE ARTICLE |
|
| Year : 2010 | Volume
: 2
| Issue : 3 | Page : 248-257 |
|
|
Human immunodeficiency virus and leishmaniasis
Navid Ezra1, Maria Teresa Ochoa1, Noah Craft2
1 Department of Medicine, Division of Dermatology, David Geffen School of Medicine at UCLA, Los Angeles, USA
2 Department of Medicine, Division of Dermatology, David Geffen School of Medicine at UCLA, Los Angeles; Department of Medicine, Divisions of Dermatology and Infectious Diseases, Harbor-UCLA Medical Center and Los Angeles Biomedical Research Institute, Torrance, CA, USA
Correspondence Address:
Noah Craft
Department of Medicine, Division of Dermatology, David Geffen School of Medicine at UCLA, Los Angeles; Department of Medicine, Divisions of Dermatology and Infectious Diseases, Harbor-UCLA Medical Center and Los Angeles Biomedical Research Institute, Torrance, CA
USA
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0974-777X.68528
|
|
|
The leishmaniases are a group of diseases transmitted to humans by the bite of a sandfly, caused by protozoan parasites of the genus Leishmania. Various Leishmania species infect humans, producing a spectrum of clinical manifestations. It is estimated that 350 million people are at risk, with a global yearly incidence of 1-1.5 million for cutaneous and 500,000 for visceral leishmaniasis (VL). VL is a major cause of morbidity and mortality in East Africa, Brazil and the Indian subcontinent. Co-infection with human immunodeficiency virus (HIV) alters the immune response to the disease. Here we review the immune response to Leishmania in the setting of HIV co-infection. Improved understanding of the immunology involved in co-infections may help in designing prophylactic and therapeutic strategies against leishmaniasis. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
